Abstract
# {#article-title-2} Trampe et al.1 should be commended for their investigation into the rate of seropositivity of the anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab. Further points need to be considered. Trampe et al.1 investigated the rate of anti-JCV antibodies by using a confirmatory 2-step ELISA on 2,782 blood samples. Although the serum sample is a good option for the detection of anti-JCV antibodies by ELISA method, it would be more accurate if they measured JVC-DNA in the urine samples of …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
